Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis (SIMM)
Sponsor: CSL Behring
Terminated
Study stopped by sponsor due to difficulty enrolling at site
Other terminated trials from CSL Behring
Other Myasthenia Gravis trials with similar outcome
A PHASE1 clinical study on Myasthenia Gravis, this trial is terminated or withdrawn. The trial is conducted by CSL Behring and has accumulated 9 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
May 2019 — Jan 2021 [monthly]
Terminated PHASE1
Phase: NA → PHASE1
▶ Show 4 earlier versions
-
Jun 2018 — May 2019 [monthly]
Terminated NA
-
Jan 2018 — Jun 2018 [monthly]
Terminated NA
-
Feb 2017 — Jan 2018 [monthly]
Terminated NA
-
Jan 2017 — Feb 2017 [monthly]
Terminated NA
First recorded
Oct 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CSL Behring
- St. Louis University
For direct contact, visit the study record on ClinicalTrials.gov .